Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Response.

Gillmeyer KR, Lee MM, Link AP, Klings ES, Rinne ST, Wiener RS.

Chest. 2019 May;155(5):1077-1078. doi: 10.1016/j.chest.2019.02.003. No abstract available.

PMID:
31060692
2.

Multisystem Healthcare Use among U.S. Veterans with Pulmonary Hypertension.

Gillmeyer KR, Lee KM, Shao Q, Miller DR, Maron BA, Klings ES, Rinne ST, Soylemez Wiener R.

Ann Am Thorac Soc. 2019 Aug;16(8):1072-1074. doi: 10.1513/AnnalsATS.201902-109RL. No abstract available.

PMID:
31026406
3.

Accuracy of Algorithms to Identify Pulmonary Arterial Hypertension in Administrative Data: A Systematic Review.

Gillmeyer KR, Lee MM, Link AP, Klings ES, Rinne ST, Wiener RS.

Chest. 2019 Apr;155(4):680-688. doi: 10.1016/j.chest.2018.11.004. Epub 2018 Nov 22.

PMID:
30471268
4.

Bronchodilator Use for Acute Chest Syndrome Among Large Pediatric Hospitals in North America.

Kopel LS, Klings ES, Monuteaux MC, Gaffin JM, Heeney MM, Phipatanakul W.

Clin Pediatr (Phila). 2018 Dec;57(14):1630-1637. doi: 10.1177/0009922818796661. Epub 2018 Sep 3.

PMID:
30173539
5.

A Triazole Disulfide Compound Increases the Affinity of Hemoglobin for Oxygen and Reduces the Sickling of Human Sickle Cells.

Nakagawa A, Ferrari M, Schleifer G, Cooper MK, Liu C, Yu B, Berra L, Klings ES, Safo RS, Chen Q, Musayev FN, Safo MK, Abdulmalik O, Bloch DB, Zapol WM.

Mol Pharm. 2018 May 7;15(5):1954-1963. doi: 10.1021/acs.molpharmaceut.8b00108. Epub 2018 Apr 18.

6.

Phosphodiesterase-5 Inhibitor Therapy for Pulmonary Hypertension in the United States. Actual versus Recommended Use.

Kim D, Lee KM, Freiman MR, Powell WR, Klings ES, Rinne ST, Miller DR, Rose AJ, Wiener RS.

Ann Am Thorac Soc. 2018 Jun;15(6):693-701. doi: 10.1513/AnnalsATS.201710-762OC.

PMID:
29485908
7.

Commentary: Heterogeneity of respiratory disease in children and young adults with sickle cell disease.

Cohen RT, Klings ES.

Thorax. 2018 Jun;73(6):503. doi: 10.1136/thoraxjnl-2017-211370. Epub 2018 Jan 20. No abstract available.

PMID:
29353255
8.

Standard measures for sickle cell disease research: the PhenX Toolkit sickle cell disease collections.

Eckman JR, Hassell KL, Huggins W, Werner EM, Klings ES, Adams RJ, Panepinto JA, Hamilton CM.

Blood Adv. 2017 Dec 15;1(27):2703-2711. doi: 10.1182/bloodadvances.2017010702. eCollection 2017 Dec 26.

9.

Clinical and laboratory findings associated with sleep disordered breathing in sickle cell disease.

Worsham CM, Martin ST, Nouraie SM, Cohen RT, Klings ES.

Am J Hematol. 2017 Dec;92(12):E649-E651. doi: 10.1002/ajh.24892. Epub 2017 Oct 27. No abstract available.

10.

Prostacyclin-analog therapy in sickle cell pulmonary hypertension.

Weir NA, Saiyed R, Alam S, Conrey A, Desai HD, George MP, Keeley JH, Klings ES, Mehari A, Taylor JG 6th, Minniti CP, Kato GJ.

Haematologica. 2017 May;102(5):e163-e165. doi: 10.3324/haematol.2015.131227. Epub 2017 Jan 25. No abstract available.

11.

Sickle cell disease: wheeze or asthma?

Cohen RT, Klings ES, Strunk RC.

Asthma Res Pract. 2015 Dec 8;1:14. doi: 10.1186/s40733-015-0014-2. eCollection 2015. Review.

12.

Sleep-disordered breathing and nocturnal hypoxemia in young adults with sickle cell disease.

Whitesell PL, Owoyemi O, Oneal P, Nouraie M, Klings ES, Rock A, Mellman TA, Berihun T, Lavella J, Taylor RE, Perrine SP.

Sleep Med. 2016 Jun;22:47-49. doi: 10.1016/j.sleep.2016.05.006. Epub 2016 Jun 23.

13.

Chronic Pulmonary Complications of Sickle Cell Disease.

Mehari A, Klings ES.

Chest. 2016 May;149(5):1313-24. doi: 10.1016/j.chest.2015.11.016. Epub 2016 Jan 13. Review.

14.

Long-term Exercise After Pulmonary Rehabilitation (LEAP): Design and rationale of a randomized controlled trial of Tai Chi.

Moy ML, Wayne PM, Litrownik D, Beach D, Klings ES, Davis RB, Yeh GY.

Contemp Clin Trials. 2015 Nov;45(Pt B):458-467. doi: 10.1016/j.cct.2015.09.004. Epub 2015 Sep 8.

15.

Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia.

Morris CR, Kim HY, Klings ES, Wood J, Porter JB, Trachtenberg F, Sweeters N, Olivieri NF, Kwiatkowski JL, Virzi L, Hassell K, Taher A, Neufeld EJ, Thompson AA, Larkin S, Suh JH, Vichinsky EP, Kuypers FA; Thalassemia Clinical Research Network.

Br J Haematol. 2015 Jun;169(6):887-98. doi: 10.1111/bjh.13452. Epub 2015 Apr 24.

16.

Pulmonary hypertension in sickle cell disease: diagnosis and management.

Ataga KI, Klings ES.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):425-31. doi: 10.1182/asheducation-2014.1.425. Epub 2014 Nov 18. Review.

PMID:
25696889
17.

Management of patients with sickle cell disease.

Klings ES, Kato GJ, Gladwin MT.

JAMA. 2015 Jan 6;313(1):91. doi: 10.1001/jama.2014.15898. No abstract available.

18.

Pulmonary hypertension in sickle cell disease.

Hayes MM, Vedamurthy A, George G, Dweik R, Klings ES, Machado RF, Gladwin MT, Wilson KC, Thomson CC; American Thoracic Society Implementation Task Force.

Ann Am Thorac Soc. 2014 Nov;11(9):1488-9. doi: 10.1513/AnnalsATS.201408-405CME. No abstract available.

19.

Reply: Practice guideline for pulmonary hypertension in sickle cell: direct evidence needed before universal adoption.

Klings ES, Machado RF, Morris CR, Gordeuk VR, Kato GJ, Ataga KI, Castro O, Hsu L, Telen MJ, Krishnamurti L, Steinberg MH, Gladwin MT; ATS Clinical Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension in Sickle Cell Disease Committee.

Am J Respir Crit Care Med. 2014 Jul 15;190(2):238-40. doi: 10.1164/rccm.201404-0733LE. No abstract available.

20.

Pulmonary hypertension of sickle cell disease beyond classification constraints.

Klings ES, Morris CR, Hsu LL, Castro O, Gladwin MT, Mubarak KK.

J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2881-2. doi: 10.1016/j.jacc.2014.01.081. Epub 2014 Apr 30. No abstract available.

21.

An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.

Klings ES, Machado RF, Barst RJ, Morris CR, Mubarak KK, Gordeuk VR, Kato GJ, Ataga KI, Gibbs JS, Castro O, Rosenzweig EB, Sood N, Hsu L, Wilson KC, Telen MJ, Decastro LM, Krishnamurti L, Steinberg MH, Badesch DB, Gladwin MT; American Thoracic Society Ad Hoc Committee on Pulmonary Hypertension of Sickle Cell Disease.

Am J Respir Crit Care Med. 2014 Mar 15;189(6):727-40. doi: 10.1164/rccm.201401-0065ST.

22.
23.

Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension.

Morris CR, Kim HY, Wood J, Porter JB, Klings ES, Trachtenberg FL, Sweeters N, Olivieri NF, Kwiatkowski JL, Virzi L, Singer ST, Taher A, Neufeld EJ, Thompson AA, Sachdev V, Larkin S, Suh JH, Kuypers FA, Vichinsky EP; Thalassemia Clinical Research Network.

Haematologica. 2013 Sep;98(9):1359-67. doi: 10.3324/haematol.2012.082065. Epub 2013 Apr 12.

24.

Making it personal: using genomics to predict pulmonary hypertension in sickle cell disease.

Klings ES, Morris CR.

Am J Respir Crit Care Med. 2012 Aug 15;186(4):304-5. doi: 10.1164/rccm.201206-1126ED. No abstract available.

PMID:
22896592
25.

A genome-wide association study of total bilirubin and cholelithiasis risk in sickle cell anemia.

Milton JN, Sebastiani P, Solovieff N, Hartley SW, Bhatnagar P, Arking DE, Dworkis DA, Casella JF, Barron-Casella E, Bean CJ, Hooper WC, DeBaun MR, Garrett ME, Soldano K, Telen MJ, Ashley-Koch A, Gladwin MT, Baldwin CT, Steinberg MH, Klings ES.

PLoS One. 2012;7(4):e34741. doi: 10.1371/journal.pone.0034741. Epub 2012 Apr 27.

26.

Monocytes from sickle cell disease patients induce differential pulmonary endothelial gene expression via activation of NF-κB signaling pathway.

Safaya S, Steinberg MH, Klings ES.

Mol Immunol. 2012 Feb;50(1-2):117-23. doi: 10.1016/j.molimm.2011.12.012. Epub 2012 Jan 20.

PMID:
22264835
27.

Keeping it in the family: three relatives with HbSC disease and simultaneous acute pulmonary emboli.

Hawkins F, Ebel N, Sorescu GP, McMahon L, Sprinz P, Klings ES.

Am J Hematol. 2012 Jan;87(1):101-4. doi: 10.1002/ajh.22177. Epub 2011 Sep 26. No abstract available.

28.

Ancestry of African Americans with sickle cell disease.

Solovieff N, Hartley SW, Baldwin CT, Klings ES, Gladwin MT, Taylor JG 6th, Kato GJ, Farrer LA, Steinberg MH, Sebastiani P.

Blood Cells Mol Dis. 2011 Jun 15;47(1):41-5. doi: 10.1016/j.bcmd.2011.04.002. Epub 2011 May 4.

29.

Severe sickle cell anemia is associated with increased plasma levels of TNF-R1 and VCAM-1.

Dworkis DA, Klings ES, Solovieff N, Li G, Milton JN, Hartley SW, Melista E, Parente J, Sebastiani P, Steinberg MH, Baldwin CT.

Am J Hematol. 2011 Feb;86(2):220-3. doi: 10.1002/ajh.21928.

30.

Sickle cell anemia and vascular dysfunction: the nitric oxide connection.

Akinsheye I, Klings ES.

J Cell Physiol. 2010 Sep;224(3):620-5. doi: 10.1002/jcp.22195. Review.

PMID:
20578237
31.

Genetic modifiers of the severity of sickle cell anemia identified through a genome-wide association study.

Sebastiani P, Solovieff N, Hartley SW, Milton JN, Riva A, Dworkis DA, Melista E, Klings ES, Garrett ME, Telen MJ, Ashley-Koch A, Baldwin CT, Steinberg MH.

Am J Hematol. 2010 Jan;85(1):29-35. doi: 10.1002/ajh.21572.

32.

Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5' olfactory receptor gene cluster.

Solovieff N, Milton JN, Hartley SW, Sherva R, Sebastiani P, Dworkis DA, Klings ES, Farrer LA, Garrett ME, Ashley-Koch A, Telen MJ, Fucharoen S, Ha SY, Li CK, Chui DH, Baldwin CT, Steinberg MH.

Blood. 2010 Mar 4;115(9):1815-22. doi: 10.1182/blood-2009-08-239517. Epub 2009 Dec 16.

33.

Hyperoxia-induced lung injury in gamma-glutamyl transferase deficiency is associated with alterations in nitrosative and nitrative stress.

Klings ES, Lowry MH, Li G, Jean JC, Fernandez BO, Garcia-Saura MF, Feelisch M, Joyce-Brady M.

Am J Pathol. 2009 Dec;175(6):2309-18. doi: 10.2353/ajpath.2009.081017. Epub 2009 Oct 22.

34.

Effect of sodium butyrate on lung vascular TNFSF15 (TL1A) expression: differential expression patterns in pulmonary artery and microvascular endothelial cells.

Safaya S, Klings ES, Odhiambo A, Li G, Farber HW, Steinberg MH.

Cytokine. 2009 Apr;46(1):72-8. doi: 10.1016/j.cyto.2008.12.013. Epub 2009 Feb 28.

35.

Pulmonary arterial hypertension and left-sided heart disease in sickle cell disease: clinical characteristics and association with soluble adhesion molecule expression.

Klings ES, Anton Bland D, Rosenman D, Princeton S, Odhiambo A, Li G, Bernard SA, Steinberg MH, Farber HW.

Am J Hematol. 2008 Jul;83(7):547-53. doi: 10.1002/ajh.21187.

36.
37.

Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease.

Morris CR, Suh JH, Hagar W, Larkin S, Bland DA, Steinberg MH, Vichinsky EP, Shigenaga M, Ames B, Kuypers FA, Klings ES.

Blood. 2008 Jan 1;111(1):402-10. Epub 2007 Sep 11.

38.

Identification of oxidative post-translational modification of serum albumin in patients with idiopathic pulmonary arterial hypertension and pulmonary hypertension of sickle cell anemia.

Odhiambo A, Perlman DH, Huang H, Costello CE, Farber HW, Steinberg MH, McComb ME, Klings ES.

Rapid Commun Mass Spectrom. 2007;21(14):2195-203.

PMID:
17569101
39.
40.

Abnormal pulmonary function in adults with sickle cell anemia.

Klings ES, Wyszynski DF, Nolan VG, Steinberg MH.

Am J Respir Crit Care Med. 2006 Jun 1;173(11):1264-9. Epub 2006 Mar 23.

41.

Differential gene expression in pulmonary artery endothelial cells exposed to sickle cell plasma.

Klings ES, Safaya S, Adewoye AH, Odhiambo A, Frampton G, Lenburg M, Gerry N, Sebastiani P, Steinberg MH, Farber HW.

Physiol Genomics. 2005 May 11;21(3):293-8. Epub 2005 Mar 1.

PMID:
15741505
42.

Sickle cell vaso-occlusive crisis induces the release of circulating serum heat shock protein-70.

Adewoye AH, Klings ES, Farber HW, Palaima E, Bausero MA, McMahon L, Odhiambo A, Surinder S, Yoder M, Steinberg MH, Asea A.

Am J Hematol. 2005 Mar;78(3):240-2.

43.

Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.

Klings ES, Farber HW.

N Engl J Med. 2004 Jun 10;350(24):2521-2; author reply 2521-2. No abstract available.

PMID:
15190149
44.

The pathogenesis of HIV-associated pulmonary hypertension.

Klings ES, Farber HW.

Adv Cardiol. 2003;40:71-82. Review. No abstract available.

PMID:
14533547
45.

Cellular glutathione peroxidase deficiency and endothelial dysfunction.

Forgione MA, Weiss N, Heydrick S, Cap A, Klings ES, Bierl C, Eberhardt RT, Farber HW, Loscalzo J.

Am J Physiol Heart Circ Physiol. 2002 Apr;282(4):H1255-61.

46.

Current management of primary pulmonary hypertension.

Klings ES, Farber HW.

Drugs. 2001;61(13):1945-56. Review.

PMID:
11708765
47.

Role of free radicals in the pathogenesis of acute chest syndrome in sickle cell disease.

Klings ES, Farber HW.

Respir Res. 2001;2(5):280-5. Epub 2001 Jul 13. Review.

48.

Increased F2 isoprostanes in the acute chest syndrome of sickle cell disease as a marker of oxidative stress.

Klings ES, Christman BW, McClung J, Stucchi AF, McMahon L, Brauer M, Farber HW.

Am J Respir Crit Care Med. 2001 Oct 1;164(7):1248-52.

PMID:
11673218
49.

Lipopolysaccharide binding protein potentiates airway reactivity in a murine model of allergic asthma.

Strohmeier GR, Walsh JH, Klings ES, Farber HW, Cruikshank WW, Center DM, Fenton MJ.

J Immunol. 2001 Feb 1;166(3):2063-70.

50.

IV epoprostenol for systemic sclerosis.

Klings ES, Farber HW.

Chest. 2000 Sep;118(3):881-2. No abstract available.

PMID:
10988225

Supplemental Content

Loading ...
Support Center